In a clinical trial (NCT03056339) targeting CD19-positive lymphoid tumors, NK cells were transduced to express genes encoding anti-CD19 CAR, IL-15, and inducible caspase 9 as a safety switch. Here, CD19 is linked to lymphoid neoplasm.